Comparison tool
KPV vs Enfuvirtide side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | KPV | Enfuvirtide |
|---|---|---|
| Category | Immune | Immune |
| Also known as | Lys-Pro-Val, Alpha-MSH fragment | Fuzeon, T-20 |
| FDA approved | No | Yes |
| Clinical status | Preclinical research ongoing; no human clinical-trial benefit evidence was provided
| FDA approved; source also reports commercial discontinuation in February 2025 and withdrawal from US, UK, and Canadian markets.
|
| What to expect | Gut inflammation, IBD, skin conditions and anti-inflammatory activity | HIV treatment, viral infection management |
| How it works | KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway. | Enfuvirtide is described as a peptide HIV fusion inhibitor that targets gp41. It resembles the HR2 segment of gp41 and binds the HR1 region, disrupting the conformational pairing needed to draw viral and host-cell membranes together. Because that fusion step is blocked, the virus is prevented from entering the cell through this pathway. |
| Typical dosing | 200-500 mcg daily · 1-2x daily | Limited community data available · See research protocols |
| Research dosing | 200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules | 90 mg subcutaneous twice daily · Twice daily · Ongoing as part of HIV regimen · Subcutaneous injection twice daily |
| Typical duration | 4-8 weeks typical | Ongoing as part of HIV regimen |
| Administration | Subcutaneous injection or oral capsules | Subcutaneous injection twice daily |
| Timing | Morning, or as directed in the source context With or without food | Morning or as directed With or without food |
| Evidence level | Preclinical | FDA Approved |
| Possible side effects |
+4 more
|
+3 more
|
| Research summary | The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses. | The source characterizes enfuvirtide as a well-studied antiretroviral peptide rather than a speculative research compound. It cites the TORO 1 and TORO 2 phase 3 trials in heavily treatment-experienced participants, where enfuvirtide added to an optimized background regimen produced larger viral-load reductions than optimized background therapy alone. The source also notes earlier dose-ranging studies in HIV-infected adults, frequent injection-site reactions, practical burden from twice-daily injections, resistance linked to gp41 HR1 mutations, and combination-regimen use. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.